ImmunityBio, Inc. research snapshot
IBRX AI stock analysis currently sees ImmunityBio as a commercial-stage immunotherapy company with fast-growing ANKTIVA revenue, expanding global approvals, and a funded pipeline, but also with price weakness, negative equity, litigation, dilution, and financing risk. At the August 3, 2026 research cutoff, the latest verified close was $7.17 on July 31 and the market capitalization was about $7.51 billion, calculated from the close and 1.05 billion shares outstanding. TTM revenue reached $140.98 million and Q1 2026 revenue reached $44.21 million, up about 168% year over year, yet the company remained loss-making with a negative book value and used roughly $294 million of operating cash in the trailing twelve months. Newer headlines include a UAE marketing authorization, FDA acceptance of a supplemental BLA for papillary disease with a January 6, 2027 PDUFA date, and securities class actions filed after the FDA flagged promotional claims. The central question is whether ANKTIVA adoption, international launches, and label expansion can outrun cash burn, dilution, clinical risk, litigation, and valuation compression. This page is informational research only and is not investment advice.
Current price
$7.17
Market cap
$7.51 billion
AI score
44 / 100
Rating
Commercial momentum with expanding approvals, but price weakness, litigation, dilution, and financing risk dominate
Trend status
Below the 50-day average of $7.68 but above the 200-day average of $5.92 after the July pullback
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | ImmunityBio has moved from development to commercialization with ANKTIVA, and global approvals are expanding, but the business is still concentrated in one early product and one core oncology franchise. | Medium-high |
| Moat | The potential moat is the IL-15 platform, regulatory approvals, clinical evidence, patents through 2035, manufacturing know-how, and physician familiarity. Adoption and long-term differentiation are not yet proven. | Medium |
| Management | Founder-scientist Patrick Soon-Shiong and CEO Richard Adcock combine scientific and commercial leadership, but related-party financing, concentrated ownership, an FDA warning letter, and securities litigation require close monitoring. | Medium |
| Financial trend | Revenue rose from $14.75 million in 2024 to $113.29 million in 2025, and TTM revenue reached $140.98 million through March 2026. Losses, cash use, and negative equity remain substantial, and Q1 2026 included a large non-operating charge. | High for reported data |
| Valuation | At about 53.27x trailing revenue and 31.42x forward sales with negative EPS and negative free cash flow, the price requires strong future sales growth, successful financing, and favorable legal and regulatory outcomes. | Medium-high |
| Technical trend | IBRX closed below its 50-day average of $7.68 but above its 200-day average of $5.92, with RSI near 43.74 neutral to slightly soft after a pullback from early-July highs. | Medium-high |
| Risk level | Risk is high because clinical and regulatory outcomes, product adoption, FDA scrutiny, litigation, financing, dilution, debt-like obligations, and sharp biotech price gaps can all change the thesis quickly. | High |
| AI confidence | Confidence is strongest for the approved indication, filings, cash use, share count, and current technical snapshot. Confidence is low for future returns, litigation results, and clinical probabilities. | Medium-high for facts |
| Investment certainty | Investment certainty is low to medium. The company has a real commercial foothold and rising approvals, but the balance sheet, litigation, and pipeline still make the outcome asymmetric and difficult to underwrite. | Low-medium |
IBRX AI stock forecast
The IBRX AI stock forecast uses conditional price bands rather than a fixed target. A PE-based model is not meaningful while EPS and free cash flow are negative, so these ranges are research scenarios tied to revenue adoption, approvals, cash needs, litigation outcomes, and dilution. The consensus tracked by S&P Global was Strong Buy from four analysts with an average target near $12.75 as of June 2, 2026, which is a market estimate, not a guarantee. Recalculate after every filing or major clinical, regulatory, and legal event.
$12 to $15
More likely if ANKTIVA revenue continues to compound, international launches such as the UAE, EU, Saudi Arabia, and Macau become material, the papillary sBLA advances on schedule, the BCG-naive trial reads out positively, and financing and litigation are resolved without severe dilution or damage.
$5 to $9
More likely if revenue keeps growing but commercialization costs, R&D, interest and revenue-interest payments, and equity issuance remain high, leaving investors to value IBRX on execution rather than current earnings, with litigation and FDA scrutiny as an ongoing overhang.
$2 to $4
More likely if ANKTIVA uptake slows, trials or regulatory reviews disappoint, financing turns punitive, dilution accelerates, litigation or FDA communications damage demand, or debt-like obligations absorb the value available to common shareholders.
IBRX AI technical analysis
IBRX AI technical analysis uses the July 31, 2026 close and the latest public technical snapshot reviewed on August 2. Price closed below the 50-day average of $7.68 but above the 200-day average of $5.92, and RSI near 43.74 was neutral to slightly soft after a pullback from early-July highs. The stock remains a high-volatility biotech name with a wide 52-week range of $1.95 to $12.43. Confirm all levels on a live chart before acting because this static page does not fetch request-time market data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $7.17 | Latest verified close on July 31, 2026, used for the August 3 research cutoff. |
| Near support | $6.65 to $6.80 | Recent July lows; the July 28 intraday low was about $6.65. |
| Secondary support | $5.90 to $6.00 | Planning zone around the reported 200-day moving average of $5.92. |
| Near resistance | $7.68 | The reported 50-day moving average. A reclaim of this area would signal short-term stabilization. |
| Secondary resistance | $8.00 to $8.15 | July 21 to July 22 intraday highs near $8.10 to $8.14. |
| 52-week resistance | $12.40 to $12.43 | The upper end of the reported 52-week range and a major supply area if price rallies. |
| 50-day moving average | $7.68 | Latest StockAnalysis statistics snapshot reviewed August 2, 2026. |
| 200-day moving average | $5.92 | Latest StockAnalysis statistics snapshot reviewed August 2, 2026. |
| Momentum | RSI 43.74 | Neutral to slightly soft in the reviewed snapshot. RSI can change quickly after biotech or legal news. |
| Volume | 9.29 million shares on July 31; 20-day average 9.48 million | Recent volume has been close to the average, so a durable breakout should show expanding participation. |
| Volatility and invalidation | High; close below $6.65 to $6.80, then $5.92 | The 52-week range was $1.95 to $12.43. A close below the recent lows weakens the near-term trend; a break below the 200-day area challenges the longer trend. |
IBRX AI trading strategy
The IBRX AI trading strategy is a rules-based research framework, not personalized advice. It combines price confirmation with product revenue, cash use, financing, litigation, regulatory events, and clinical milestones because technical signals alone can fail around biotech catalysts.
Treat a move back above $7.68 and toward the $8.00 to $8.15 zone as technically stronger only if volume expands and the company continues to report ANKTIVA adoption, cash discipline, and favorable regulatory and legal progress.
A failed reclaim or daily close back below the $6.65 to $6.80 support zone reduces confidence in the setup.
If IBRX pulls back toward the 200-day area near $5.92 while revenue, regulatory progress, and liquidity remain intact, compare price stabilization with the next filing before considering a mean-reversion thesis.
Do not average down only because the stock is below a recent high. Define a maximum loss and review dilution, litigation, and financing risk first.
Monitor quarterly ANKTIVA revenue, international commercial availability, the papillary sBLA with a January 6, 2027 PDUFA date, the BCG-naive trial, clinical readouts, cash runway, ATM issuance, warrant exercises, FDA communications, and litigation developments.
Binary events and legal headlines can create gaps through any stop. Use position sizing and event exposure limits that match the possibility of a rapid loss.
Investment research summary
ImmunityBio develops and commercializes immunotherapies that aim to activate the immune system. The business is anchored by ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer, with approvals expanding to additional bladder and lung cancer settings and geographies.
The potential moat is a combination of IL-15 platform know-how, regulatory approvals, clinical data, patents through 2035, manufacturing capabilities, and physician familiarity. It is narrower and less proven than the moat of an established pharmaceutical franchise.
The thesis can fail if physician adoption slows, the approved market stays small, label expansion misses, clinical data disappoints, regulatory or legal scrutiny damages demand, financing becomes punitive, or revenue-interest and debt obligations absorb the commercial upside.
Patrick Soon-Shiong provides founder and scientific leadership while Richard Adcock leads as president and CEO. The company has executed an expanding ANKTIVA launch and multiple trials, but related-party debt, concentrated ownership, warrants, equity issuance, an FDA warning letter, and litigation create governance, compliance, and dilution questions.
Oncology immunotherapy is a long-term medical trend, but it is crowded and evidence-driven. IBRX participates in a large potential market while the near-term addressable market remains limited by approved indications, reimbursement, competition, and trial success.
At about 53.27x trailing revenue, 31.42x forward sales, negative EPS, negative free cash flow, negative equity, and a market capitalization far above current annual sales, the stock price implies years of successful growth. The margin of safety depends on execution, financing, and the resolution of legal and regulatory risk, not current earnings power.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IBRX price | $7.17, July 31, 2026 close; $7.19 after hours | StockAnalysis quote | August 3, 2026 |
| Market capitalization | $7.51 billion, verified as $7.17 x 1.05 billion shares with 0.25% calculation variance | StockAnalysis and financial_rigor.py | August 3, 2026 |
| Shares outstanding | 1.05 billion, up 29.76% year over year | StockAnalysis statistics | August 3, 2026 |
| TTM revenue | $140.98 million, up 351.5% from the prior trailing twelve months | StockAnalysis and Fiscal.ai | August 3, 2026 |
| FY2025 revenue | $113.29 million in StockAnalysis, approximately $113 million in the company release, up about 668% to 700% year over year | StockAnalysis and ImmunityBio FY2025 release | August 3, 2026 |
| Q1 2026 revenue | $44.21 million, up 167.64% year over year; the company reports net product revenue up nearly 2.7x to about $44 million | StockAnalysis and ImmunityBio Q1 2026 release | August 3, 2026 |
| Cash and marketable securities | $380.88 million at March 31, 2026 | StockAnalysis and ImmunityBio Q1 2026 release | August 3, 2026 |
| Debt and net cash | $1.12 billion total debt and net cash of about -$743.73 million, or -$0.71 per share | StockAnalysis statistics | August 3, 2026 |
| Earnings and losses | TTM net loss $854.53 million, partly due to a large non-operating charge reported in Q1 2026; FY2025 net loss $351.40 million; TTM EPS about -$0.89 | StockAnalysis and Fiscal.ai income statement | August 3, 2026 |
| Cash flow | TTM operating cash flow -$294.39 million and free cash flow -$298.89 million; FY2025 operating cash flow -$304.94 million | StockAnalysis statistics and financials | August 3, 2026 |
| Valuation math | P/S about 53.27x TTM and 31.42x forward; EV/Sales about 58.54x; P/E and P/FCF are not meaningful with negative EPS and free cash flow | StockAnalysis statistics and financial_rigor.py | August 3, 2026 |
| Technical inputs | 50-day MA $7.68, 200-day MA $5.92, RSI 43.74, 20-day average volume 9.48 million, short interest 12.83% of shares out and 34.10% of float | StockAnalysis statistics | August 3, 2026 |
| Analyst consensus | Strong Buy from 4 analysts with an average price target of $12.75 and a range of $12 to $15, last updated June 2, 2026 | StockAnalysis forecast, S&P Global and TipRanks | August 3, 2026 |
| Papillary sBLA status | FDA accepted the supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease; PDUFA date January 6, 2027 | ImmunityBio press release | August 3, 2026 |
| UAE marketing authorization | United Arab Emirates authorization for ANKTIVA across BCG-unresponsive NMIBC with CIS and papillary disease and metastatic NSCLC | ImmunityBio press release | August 3, 2026 |
| Regulatory and legal risk | The FDA issued a March 2026 warning letter on promotional communications, and securities class actions were announced in May 2026 after the FDA flagged promotional claims | U.S. Food and Drug Administration and GlobeNewswire | August 3, 2026 |
| Approved indication | ANKTIVA plus BCG approved for BCG-unresponsive NMIBC with CIS, with or without papillary tumors | U.S. Food and Drug Administration | August 3, 2026 |
This IBRX AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on public filings, quote snapshots, technical data, regulatory information, legal filings, analyst estimates, and third-party sources reviewed through August 3, 2026. They may be wrong, incomplete, or outdated after new earnings, product sales, financing, clinical data, regulatory decisions, litigation, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
